Foundation Medicine Pursuing Parallel Review by FDA, CMS for FoundationOne

NEW YORK (GenomeWeb) – Foundation Medicine has decided to submit its next-generation sequencing cancer profiling test FoundationOne for parallel review by the US Food and Drug Administration and the Centers for Medicare and Medicaid Services.

FoundationOne is a test that analyzes patients' solid tumors for alterations in more than 300 genes and identifies treatments they will likely benefit from. The FDA has also decided to review FoundationOne through its Expedited Access Pathway for breakthrough devices, since there is a "large unmet need for comprehensive genomic profiling of tumors," the company said in a statement.

Foundation is seeking FDA approval for the test as a tool to identify which patients will benefit from FDA-approved treatments, and also as a tool that can direct patients to clinical trials according to the molecular features of their tumors. "If approved, FoundationOne could be the first FDA-approved comprehensive genomic profiling assay to incorporate multiple companion diagnostics to support precision medicine in oncology, including an indication for use as a companion diagnostic across a diverse range of solid tumors," Foundation added.

In anticipation of having to evaluate an NGS test for companion diagnostic use, the FDA held a public workshop earlier this year with test developers to discuss how it should evaluate the preanalytical, analytical, and clinical validity aspects of such tests, and to consider how they should be labeled.

The Parallel Review pathway, meanwhile, enables test developers to simultaneously obtain premarket approval and clearance through the FDA and a national coverage determination through CMS — a six to nine-month process by which CMS determines if it will pay for a product or service that it deems "reasonable and necessary" for the Medicare population.

Although the agencies have touted that parallel review can expedite the time it takes to commercially launch a product and garner reimbursement, few test developers have utilized the strategy. Exact Sciences is the only firm to successfully navigate parallel review for its colorectal cancer DNA screening test Cologuard by conducting a 10,000-patient study.

Following discussions with FDA and CMS, Foundation estimated the agencies could complete their parallel review of FoundationOne in the second half of 2017. While the test is being reviewed, CEO Michael Pellini said that the company will continue to work with Medicare contractors and Palmetto's MolDx program to expand local coverage determinations for genomic profiling tests like FoundationOne. To date, a number of Medicare contractors have issued LCDs outlining coverage criteria for genomic sequencing panels in advanced non-small cell lung cancer.

"Pursuing avenues at both the local and national levels maximizes the opportunity for Medicare beneficiaries with cancer to have access to FoundationOne," Pellini said in a statement.

The company also believes that FDA approval of FoundationOne as a platform that comprises multiple companion diagnostics will also bolster its pharmaceutical partnerships. "We believe this approach, which is designed to expedite approval of additional biomarkers on FoundationOne, both accelerates and de-risks companion diagnostic approval for our biopharma partners seeking a coordinated regulatory strategy for therapeutic drug approval," Pellini added.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.

Sep
07
Sponsored by
PerkinElmer

This webinar will address improvements in the library prep workflow for small RNA sequencing in serum and plasma.

Sep
20
Sponsored by
Ion Torrent

This webinar will discuss how next-generation sequencing (NGS) can help clinical research labs and pathologists save time, money, and samples compared to single-analyte oncology research assays.

Sep
21
Sponsored by
Roche

This webinar will demonstrate a new approach that combines precise FFPE tumor isolation with extraction-free DNA/RNA library preparation to minimize material losses and reduce the amount of tissue input required for NGS analysis.

Sep
26
Sponsored by
PerkinElmer

This webinar will describe a protocol and proof-of-principle experiments for Cellular Indexing of Transcriptome and Epitopes by Sequencing (CITE-seq).